Jeffrey Schulman
Child & Adolescent Psychiatry · Saint Louis, MONPI 1275688798
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $47,412 of the $62,047 with a category attached, or 76.4%. 18 manufacturers reported payments, led by Corium, LLC at 48.1% of the total. Reporting peaked in 2021 at $30,227 and has fallen 58.8% since, to $12,459 in 2023. Among child & adolescent psychiatry clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 217 payments — averaging $285.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$30K
- Supernus Pharmaceuticals, Inc.$30K
- AbbVie$457
- Otsuka America Pharmaceutical, Inc.$326
- Takeda Pharmaceuticals U.S.A., Inc.$317
- Ironshore Pharmaceuticals Inc.$225
- plus $1K from 12 others
What the payments were for
- Consulting fees$7,65012%
- Speaking & faculty fees$47,41276%
- Travel & lodging$3,0975%
- Food & beverage$3,8096%
- Education$790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corium, LLC | 35 | $29,870 |
| Supernus Pharmaceuticals, Inc. | 39 | $29,844 |
| AbbVie(2 entities) | 28 | $457 |
| Otsuka America Pharmaceutical, Inc. | 15 | $326 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $317 |
| Ironshore Pharmaceuticals Inc. | 8 | $225 |
| Sunovion Pharmaceuticals Inc. | 16 | $203 |
| Johnson & Johnson | 12 | $172 |
| Rhodes Pharmaceuticals L.p. | 12 | $150 |
| Axsome Therapeutics, Inc. | 4 | $114 |
| Shire North American Group Inc | 6 | $96 |
| Tris Pharma Inc | 6 | $81 |
| Neos Therapeutics, LP | 3 | $52 |
| Adlon Therapeutics L.p. | 3 | $45 |
| Noven Therapeutics, LLC | 2 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $34 |
| Vertical Pharmaceuticals, LLC | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Azstarys$29,691
- QELBREE$25,338
- REXULTI$122
- VRAYLAR$112
- Jornay PM 20mg capsules (Bottle of 100)$112
How this compares
$62,047 in reported general payments places this provider in the 95th percentile of 90 child & adolescent psychiatry providers in Missouri.
See all child & adolescent psychiatry providers in Missouri →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 15 | $292 |
| Lurasidone Hcl | 14 | $230 |
| Risperidone | 17 | $167 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Saint Louis
- Ginger NicolSaint Louis$77K
- Joshua WilsonSaint Louis$22K
- Michael BantonSaint Louis$3K
- Chad SylvesterSaint Louis$3K
- Paul GlaserSaint Louis$3K
- Oksana BaramSaint Louis$2K
- Afshan SultanaSaint Louis$1K
- Kelly BotteronSaint Louis$887
- Stephen IrwinSaint Louis$683
- Darin QuachSaint Louis$629
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.